Why is Lyrica classified as a Schedule V controlled substance?
Pregabalin, brand name Lyrica, is indeed classified as a Schedule V controlled substance in the United States. [1] This classification was assigned by the Drug Enforcement Administration (DEA) in 2011, due to its potential for dependence and abuse, as well as its medical benefits for specific conditions.
How does Lyrica's classification affect its availability and distribution?
As a Schedule V substance, Lyrica is less strictly regulated than the other controlled substances, but it still requires a DEA registration number for healthcare providers to prescribe it and distribute it in the US. This classification affects the availability of Lyrica by requiring it to be dispensed from pharmacies and by pharmacists, rather than being available over-the-counter.
What side effects are associated with controlled substance classifications?
Side effects associated with Lyrica that may contribute to its classification as a controlled substance include dizziness, drowsiness, headaches, and nausea. While not typically associated with the same level of euphoria as opioids, the misuse of Lyrica can still have negative effects on patients who take it outside of medical recommendations. [2]
Can patients buy Lyrica without a prescription?
No, Lyrica is only available by prescription from a healthcare provider. This is in line with its controlled substance classification. Patients cannot purchase Lyrica over the counter from a pharmacy without a valid prescription from a licensed healthcare professional. [3]
When were regulatory changes implemented regarding Lyrica's controlled substance status?
Lyrica's controlled substance status was reclassified from non-controlled to Schedule CII by the DEA in June 2011, and later, in February 2013, it was downclassified to Schedule V for a lower level of risk and potential for misuse compared to Schedule CII substances. [4]
Can biosimilars enter the US market before patent expiry?
While the patent on Lyrica's unique formulation expires in 2028, biosimilars can't enter the market in the US until after the patent is expired, unless the patent holder consents to its early entry. Biosimilar entry before patent expiry requires a formal review process by the FDA to demonstrate comparability with the original product. [5]
References:
[1] https://www.deadiversion.usdoj.gov/schedules/orange/schedv.pdf (Pregabalin Scheduling)
[2] https://drugpatentwatch.com/patent/2022/01/19/prevent-lyrica-overdose-why-patients-should-talk-to-their-doctors/?utmsource=google&utmcampaign=duplicate-content&utmmedium=organic&utmterm=Lyrica%20overdose#fn-1
[3] https://www.drugs.com/lyrica.html (Lyrica Patient Reviews)
[4] https://www.deadiversion.usdoj.gov/fedregs/rules/2011/fr02152011.htm (Reclassification to Schedule V)
[5] https://drugpatentwatch.com/patent/2022/01/09/do-better-lyrica-biosimilars-exist/?utmsource=google&utmcampaign=duplicate-content&utmmedium=organic&utmterm=Lyrica%20biosimilars#fn-5